Navigation Links
FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
Date:2/29/2008

mended.

-- Treatment with venlafaxine is associated with sustained increases in

blood pressure (BP) in some patients. Postmarketing cases of elevated

BP requiring immediate treatment have been reported. Pre-existing

hypertension should be controlled. Regular BP monitoring is

recommended.

-- SSRIs and SNRIs, including EFFEXOR XR, may increase the risk of

bleeding events. Concomitant use of aspirin, NSAIDs, warfarin, and

other anticoagulants may add to this risk.

-- Mydriasis has been reported in association with venlafaxine; therefore,

patients with raised intraocular pressure or those at risk of acute

narrow-angle glaucoma (angle-closure glaucoma) should be monitored.

-- Abrupt discontinuation or dose reduction has been associated with

discontinuation symptoms. Patients should be counseled on possible

discontinuation symptoms and monitored while discontinuing the drug;

the dose should be tapered gradually.

-- The most common adverse events reported in EFFEXOR XR short-term

placebo-controlled MDD, generalized anxiety disorder (GAD), social

anxiety disorder (SAD), and/or panic disorder (PD) trials (incidence

greater than or equal to 10% and greater than or equal to 2x that of

placebo) were anorexia, asthenia, constipation, dizziness, dry mouth,

ejaculation problems, impotence, insomnia, nausea, nervousness,

somnolence, and sweating.

For full prescribing information for EFFEXOR XR, please go to http://www.EffexorXR.com.

About Wyeth Pharmaceuticals

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
2. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
3. FDA Approves New Mechanism of Action Labeling for Ranexa(R)
4. FDA Approves Diovan(R) for Treatment of High Blood Pressure in Children
5. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
6. FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
9. FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
10. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Polaris Group announced today that the ... 1 trial of ADI-PEG 20 in combination with ... pleural mesothelioma (MPM) and non-squamous non-small cell lung ... ADI-PEG 20, both as monotherapy and in combination ... other indications, including breast cancer, melanomas, ovarian cancer, ...
(Date:11/18/2014)... , Nov. 18, 2014 Cord Blood ... sponsor of the 10th Annual World Stem Cell Summit, the ... stakeholders. The 2014 World Stem Cell Summit will be held ... Antonio, Texas . The World ... development of lifesaving cures and therapies, convening the most prominent ...
(Date:11/18/2014)... Diego, CA (PRWEB) November 17, 2014 Athena ... of Salk , Dr. Beverly Emerson, a professor in the ... of genes. Her most recent discovery points to an “off ... Dr. Emerson’s career and how her local research is making ... will present her findings and then join host Cheryl K. ...
(Date:11/18/2014)... 2014 2014 Deep Research ... professional and in-depth report on Polytetrahydrofuran (PTMEG) ... including its definition, characterization, application, and industry ... exploration covers the worldwide business investigation, including ... covering macroeconomic environment & financial circumstance examination. ...
Breaking Biology Technology:Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 2Cord Blood Registry Sponsors 2014 World Stem Cell Summit 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3
... March 14 Kendle (Nasdaq: KNDL ), ... Senior Vice President and Chief Financial Officer Karl,"Buzz" ... Eleventh,Annual Global Healthcare Conference. The conference will be ... Florida, March 18-20, 2008. Kendle,s,presentation is scheduled for ...
... Diagnostics,Incorporated (NYSE: DGX ), the nation,s leading ... it is scheduled to speak,at the Cowen and ... March 18, 2008, at the Marriott Copley Place, ... begin at,8:45 a.m. Eastern Time., The presentation ...
... March 14 Creighton University,law, science, medical and ... it takes to convert scientific research into new ... a competitive application and,interview process -- are enrolled ... time on Feb. 13. A three-year, $536,000 National ...
Cached Biology Technology:Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference 2Quest Diagnostics to Speak at Cowen and Company 28th Annual Health Care Conference 2NSF Funds New Entrepreneurship Program 2
(Date:11/4/2014)... published research study examining only marketing directed at ... food restaurants has found that the majority of ... to such marketing tactics. , Authored by Arizona ... the study is the first to examine the ... exterior of fast food restaurants and its relationship ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and Markets ... "Cell Therapy - Technologies, Markets and Companies" to their ... therapy technologies and methods, which have already started to play ... cell transplantation is replacing the old fashioned bone marrow transplants. ... therapy is bound to become a part of medical practice. ...
(Date:11/2/2014)... issue of Physics World , James Dacey explores ... of death" to take their innovations from the lab ... gruelling challenge facing all start-up companies as they move ... because of two main factors: physics-based inventions are usually ... turn out to be a lot more complicated than ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3The 'valley of death' facing physics start-ups 2
... Los Baos, Philippines A small insect that has devastated ... over the past few yearscausing the loss of thousands of ... productionis the focus of a critical and timely conference this ... major type of rice pest that can destroy one-fifth of ...
... and Texas A & M University have discovered a ... specific tissues in animals. In studies to determine ... group previously identified a region of a smooth muscle ... of any plasmid carrying this sequence uniquely in cultured ...
... to Consultancy in Automotive, IRVINE, Calif., June 20 ... auto industry executive who has worked with,Jaguar, Audi, Volkswagen, ... The,position will be based in Irvine, Calif., and will ... responsible for managing existing,client relationships as well as developing ...
Cached Biology News:Research required urgently to control planthopper pests 2Research required urgently to control planthopper pests 3New paradigm for cell-specific gene delivery 2Len Hunt Joins Gallup Consulting Group 2
...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Assay Diluent, 10 L...
HRP Monoclonal-Goat Diluent - 5X Concentrate, 25 mL...
Biology Products: